Publicação:
Increase of lipids during HCV treatment: Virus action or medication?

dc.contributor.authorDe Andrade, Vanessa Gutierrez [UNESP]
dc.contributor.authorYamashiro, Fabio da Silva [UNESP]
dc.contributor.authorOliveira, Cassio Vieira [UNESP]
dc.contributor.authorKurozawa, Leticia Lastória [UNESP]
dc.contributor.authorMoreira, Alecsandro [UNESP]
dc.contributor.authorSilva, Giovanni Faria [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-12-11T17:21:59Z
dc.date.available2018-12-11T17:21:59Z
dc.date.issued2018-04-01
dc.description.abstractBackground - The interaction between serum lipids and C virus infection is well known, as are serum lipid levels in the Peg-IFN/RBV-based treatment. However, with direct action antivirals (DAAs) this behavior is still unclear. Objective - To compare serum lipids levels between patients treated with Peg-IFN/RBV and DAAs and to evaluate lipids in sustained virological response (SVR) with DAAs. Methods - Retro prospective study comparing the behavior of total cholesterol (TC), low-density lipoprotein (LDL) and triglycerides (TG) serum levels during treatment with DAAs (G-DAAs) and a control historic group Peg-IFN/RBV (G-PR). Coorte, prospective study, to study the behavior of lipids in the SVR with DAAs. Data were collected at the beginning of treatment (baseline: t-base) and at week 12 of treatment (t-12) for G-DAAs and at week 24 (t-24) for G-PR, groups. In the cohort evaluation, the samples at t-base and at week 12 after the end of treatment (t-SVR). Delta lipids: difference between lipids in t-12/t-24 minus t-base for comparison between G-PR and G-AADs groups and t-SVR minus t-base for lipid analysis in SVR. Analysis with Kruskal Wallis and Wilcoxon tests to compare the delta lipids of the groups. The P value was 0.05. Results - In the assessment between G-PR and G-DAAs groups, we included 63 and 121 patients, respectively. The groups did not differ one from the other (BMI, sex, genotype, fibrosis, total cholesterol, LDL, and TG) except by age (50.38 ± 10.44 vs 56 ± 9.69, P=0.0006). We observed a decrease in levels of TC and LDL and an increase in TG, in G-PR, and in G-DAAs the opposite (Δ TC -13.9 ± 34.5 vs 4.12 ± 34.3 P=0.0005, Δ LDL -7.16 ± 32 vs 10.13 ± 29.92, P=0.003, Δ TG 4.51 ± 53.7 vs -8.24 ± 49.93, P=0.0025). In the coorte analysis, we included 102 patients, 70% men and 56% F4, 95 of them reached SVR. We observed an increase of TC and LDL and a decrease of TG in both groups (SVR and non SVR), with no statistical difference (Δ TC P=0.68; Δ LDL P=0.69; Δ TG P=0.43). We did not find significant difference in delta evaluation by genotype 1 and 3 (Δ TC +29.7 ± 40.2 vs +13.4 ± 30.3, P=0.06; Δ LDL +21.4 ± 28.6 vs +16.6 ± 31.3, P=0.41; Δ TG -3.6 ± 60.6 vs -0.7 ± 40, P=0.91). Conclusion - Serum lipids level differed during treatment with Peg-IFN and DAAs. Treatment with DAAs was associated with an increase of TC and LDL and a decrease of TG, independently of SVR.en
dc.description.affiliationUniversidade Estadual Paulista ‘Júlio de Mesquita Filho’ (UNESP) Campus Botucatu Faculdade de Medicina Departamento de Clínica Médica
dc.description.affiliationUnespUniversidade Estadual Paulista ‘Júlio de Mesquita Filho’ (UNESP) Campus Botucatu Faculdade de Medicina Departamento de Clínica Médica
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.format.extent184-187
dc.identifierhttp://dx.doi.org/10.1590/s0004-2803.201800000-33
dc.identifier.citationArquivos de Gastroenterologia, v. 55, n. 2, p. 184-187, 2018.
dc.identifier.doi10.1590/s0004-2803.201800000-33
dc.identifier.fileS0004-28032018000200184.pdf
dc.identifier.issn1678-4219
dc.identifier.issn0004-2803
dc.identifier.scieloS0004-28032018000200184
dc.identifier.scopus2-s2.0-85050874724
dc.identifier.urihttp://hdl.handle.net/11449/176665
dc.language.isoeng
dc.relation.ispartofArquivos de Gastroenterologia
dc.relation.ispartofsjr0,396
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectAntiviral agents
dc.subjectHepatitis C
dc.subjectInterferon-alpha
dc.subjectLipid metabolism
dc.subjectTherapeutic use
dc.subjectVirological analysis
dc.titleIncrease of lipids during HCV treatment: Virus action or medication?en
dc.titleAumento dos lipídes durante tratamento para VHC: Ação do vírus ou da medicação?pt
dc.typeArtigo
dspace.entity.typePublication
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
S0004-28032018000200184.pdf
Tamanho:
119.51 KB
Formato:
Adobe Portable Document Format